For Abbott, Diversity Remains Paramount
When it comes to investing in Big Pharma, it's hard to top Abbott (ABT), especially as its peers continue to be beaten up.
In short-term, mid-term and long-term assessments of stock performance through Aug. 6, Abbott outpaced its rivals at each measurement most of the time. Abbott has also outperformed the Amex Pharmaceutical Index of big drugmakers at intervals of six months, 12 months, two years and five years.
"Abbott has done well with a diversified platform of nutritional products, diagnostics and devices to help offset the volatility of the pharmaceutical group," says Damien Conover of the financial research firm Morningstar. "Near-term, Abbott is set up for pretty good growth."
Growth was evident in mid-July when Abbott issued second-quarter results that beat Wall Street estimates, raised its full-year earnings forecast and predicted continued double-digit EPS growth in 2009.Abbott's steady advance over the years has pushed its market capitalization to about $90 billion, trailing only Johnson & Johnson (JNJ) and Pfizer (PFE) among U.S. Big Pharmas. Like J&J, Abbott's shares should continue to benefit from diversification, says Catherine Arnold of Credit Suisse, who gave a neutral rating in a recent report. "We prefer Abbott to J&J in this regard given their relative growth outlook," says Arnold. Her firm has had a recent investment-banking relationship. (Abbott's stock beats J&J at two-year and five-year intervals; J&J wins at six-month and 12-month intervals.) Arnold is neutral because Abbott is trading near her 12-month target of $59. Morningstar gives Abbott a four-star rating, with five being the highest, saying the stock is just below its fair value forecast of $63. The stock closed at $58.78 on Aug. 6.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV